Home » Topics » BioWorld Science

BioWorld Science
RSS

Evotec and Lilly collaborate on drug discovery for metabolic diseases

Jan. 19, 2022

BetterLife reports data from in vivo oral bioavailability and food-effect PK study with BETR-001

Jan. 19, 2022

ProMIS initiates program to develop monoclonal antibodies to treat schizophrenia

Jan. 19, 2022

Eisbach Bio and MD Anderson partner to target synthetic lethality in cancer

Jan. 19, 2022

Once-daily dermal administration of Epoladerm well tolerated in four preclinical studies

Jan. 19, 2022

Sodium salt of a quinoline derivative shows anticancer efficacy in vivo

Jan. 19, 2022

Yes targeting useful for treatment of HCC, researchers suggest

Jan. 19, 2022

Ortho-hIL-2/ortho-hIL-2Rbeta pair enhances antitumor efficacy of engineered T cells

Jan. 19, 2022

New kappa-opioid receptor agonists identified at Humanwell Pharmaceutical US

Jan. 19, 2022

Charite-Universitaetsmedizin Berlin, Sapreme Technologies present new saponin derivatives

Jan. 19, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...